gabapentin has been researched along with Addiction, Opioid in 42 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The patients who received intrathecal morphine and gabapentin also experienced a lower rate of nausea/vomiting and pruritus." | 9.41 | Gabapentin and intrathecal morphine combination therapy results in decreased oral narcotic use and more consistent pain scores after posterior spinal fusion for adolescent idiopathic scoliosis. ( Caird, MS; Hong, RA; Leis, A; Li, Y; Robbins, C; Swallow, J, 2021) |
| "From December 2012 to February 2019, 682 hospitalizations for posterior spinal fusion in adolescent idiopathic scoliosis were identified with complete inpatient data; 49% were administered gabapentin." | 8.31 | Effect of gabapentin on length of stay, opioid use, and pain scores in posterior spinal fusion for adolescent idiopathic scoliosis: a retrospective review across a multi-hospital system. ( Brenn, B; Cho, R; Poon, SC; Samdani, A; Zhang, DA, 2023) |
| " The patients who received intrathecal morphine and gabapentin also experienced a lower rate of nausea/vomiting and pruritus." | 5.41 | Gabapentin and intrathecal morphine combination therapy results in decreased oral narcotic use and more consistent pain scores after posterior spinal fusion for adolescent idiopathic scoliosis. ( Caird, MS; Hong, RA; Leis, A; Li, Y; Robbins, C; Swallow, J, 2021) |
| "From December 2012 to February 2019, 682 hospitalizations for posterior spinal fusion in adolescent idiopathic scoliosis were identified with complete inpatient data; 49% were administered gabapentin." | 4.31 | Effect of gabapentin on length of stay, opioid use, and pain scores in posterior spinal fusion for adolescent idiopathic scoliosis: a retrospective review across a multi-hospital system. ( Brenn, B; Cho, R; Poon, SC; Samdani, A; Zhang, DA, 2023) |
| "Gabapentin is commonly prescribed for chronic pain, including to patients with HIV (PWH)." | 4.12 | Sociodemographic and clinical correlates of gabapentin receipt with and without opioids among a national cohort of patients with HIV. ( Barry, DT; Becker, WC; Crystal, S; Edelman, EJ; Gordon, KS; Kerns, RD; Li, Y; Marshall, BDL; Oldfield, BJ; Rentsch, CT; Vickers-Smith, R, 2022) |
| " The general population model included age, hepatitis C virus infection, days of opioid used by type, number of cigarettes used daily, and the following medications used in the last 30 day of pregnancy: bupropion, antinausea medicines, benzodiazepines, antipsychotics, and gabapentin." | 4.02 | Development and Validation of a Model to Predict Neonatal Abstinence Syndrome. ( Cooper, WO; Dudley, J; Harrell, FE; Hartmann, K; Martin, PR; Patrick, SW; Slaughter, JC; Stratton, S, 2021) |
| "Multiple approaches are needed to mitigate gabapentin misuse, including limiting availability in institutional settings and informal channels as well as addressing the needs of drug users who experience physical pain and withdrawal symptoms." | 3.91 | An ethnographic decision model of the initiation of gabapentin misuse among prescription and/or illicit opioid (mis)user. ( Buttram, ME; Cicero, TJ; Havens, JR; Kurtz, SP, 2019) |
| " When medically indicated, limiting use of multiple psychiatric medications, particularly benzodiazepines and gabapentin, during pregnancy should be considered to improve NAS outcomes." | 3.88 | Impact of psychiatric medication co-exposure on Neonatal Abstinence Syndrome severity. ( Nikita, FNU; Saia, K; Schiff, DM; Shaw, D; Shrestha, H; Thomas, Z; Thomas-Lewis, JA; Wachman, EM; Warden, AH, 2018) |
| "People who have co-occurring Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD) carry a higher risk of adverse outcomes, including drug overdose." | 3.11 | Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder. ( Castillo, F; Comer, SD; Evans, SM; Foltin, RW; Jones, JD; Luba, RR; Mogali, S, 2022) |
| "Group A showed more withdrawal symptoms whereas the most common complain of group B was sedation particularly during the first three days." | 2.78 | The effects of gabapentin on methadone based addiction treatment: a randomized controlled trial. ( Alavinia, M; Moghadam, MS, 2013) |
| "Interestingly, opioids induce hyperalgesia via many of the same neuro-inflammatory and central sensitization processes that occur with the development of neuropathic pain." | 2.75 | Gabapentin improves cold-pressor pain responses in methadone-maintained patients. ( Compton, P; Kehoe, P; Ling, W; Sinha, K; Torrington, MA, 2010) |
| "Severity of subjective withdrawal symptoms using the Subjective Opiate Withdrawal Scale at six stages." | 2.73 | Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients. ( Kheirabadi, GR; Maracy, MR; Ranjkesh, M; Salehi, M, 2008) |
| "However, it seems that opium withdrawal symptoms are significant, especially at days 2 to 4 after discontinuation of opium." | 2.58 | Pharmacological therapies for management of opium withdrawal. ( Amato, L; Amin-Esmaeili, M; Gholami, J; Hoseinie, L; Rahimi-Movaghar, A; Yousefi-Nooraie, R, 2018) |
| "Gabapentin was removed from the protocol between 10/20/2020 and 12/31/2020 due to side effects; it was re-implemented on 1/1/2021 due to observed spikes in opioid use during its absence." | 1.91 | Effectiveness of Bariatric Surgery Targeting Opioid Prescriptions (BSTOP) protocol on postoperative pain control. ( Appiah, D; Camacho, D; Choi, J; Goriacko, P; Kim, J; Moran-Atkin, E; Pereira, X; Seu, R; Yaghdjian, V, 2023) |
| "He had a previous history of opioid use disorder (OUD) which has been in remission." | 1.91 | Management of gabapentin misuse in a patient with previous history of opioid use disorder: Case report. ( Jalilian Khave, L; Noori, M; Noroozi, A; Rahimi-Movaghar, A, 2023) |
| "0 % did so while also on a dosage of either buprenorphine or methadone, with 28." | 1.91 | Understanding motivations and use typologies of gabapentin with opioid agonist medications. ( Buttram, ME; Ellis, MS; Qureshi, R, 2023) |
| "Gabapentin was significantly less likely to be prescribed to Black or Hispanic patients, and more likely to be prescribed to female patients, those with co-occurring substance use or mood disorders, and those with comorbid physical conditions such as neuropathic pain." | 1.91 | Gabapentin Use Among Individuals Initiating Buprenorphine Treatment for Opioid Use Disorder. ( Buttram, ME; Ellis, MS; Fidalgo, TM; Grucza, RA; Tardelli, VS; Xu, KY, 2023) |
| "Gabapentin has been shown to reduce opioid use in head and neck cancer patients." | 1.72 | Effectiveness of gabapentin in reducing opioid requirements after radiation in head and neck cancer in a single institution. ( Biedermann, GB; Bollig, CA; Clark, AD; Dooley, LM; Gilley, DR; Wieser, ME, 2022) |
| "Younger age, male gender, neuropathic pain diagnosis and pregabalin use were significantly associated with higher levels of gabapentinoid misuse." | 1.62 | Prevalence of and Factors Associated with Gabapentinoid Use and Misuse Among Texas Medicaid Recipients. ( Barner, JC; Evoy, KE; Ibiloye, EA; Lawson, KA; Peckham, AM; Rascati, KL, 2021) |
| "Substance use is prevalent in Canada, yet treatment is inaccessible." | 1.56 | A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use. ( Hulme, J; Sheikh, H; Wiercigroch, D, 2020) |
| "Persons with opioid use disorder (OUD) are at increased risk for gabapentin misuse." | 1.56 | Prescribed and non-prescribed gabapentin use among persons seeking inpatient opioid detoxification. ( Anderson, BJ; Bailey, GL; Conti, MT; Kenney, SR; Stein, MD, 2020) |
| "To evaluate the association between perioperative coadministration of gabapentinoids and opioids with inpatient opioid-related adverse events in surgical patients." | 1.56 | Association of Gabapentinoids With the Risk of Opioid-Related Adverse Events in Surgical Patients in the United States. ( Bateman, BT; Bykov, K; Franklin, JM; Patorno, E; Vine, SM, 2020) |
| "All patients had substance use disorders, the large majority (72 %) to more than one substance." | 1.43 | Abuse of Gabapentin is Associated with Opioid Addiction. ( Bastiaens, L; Galus, J; Mazur, C, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.38) | 18.2507 |
| 2000's | 1 (2.38) | 29.6817 |
| 2010's | 19 (45.24) | 24.3611 |
| 2020's | 21 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 2 |
| Swallow, J | 1 |
| Robbins, C | 1 |
| Caird, MS | 1 |
| Leis, A | 1 |
| Hong, RA | 1 |
| Ellis, MS | 5 |
| Buttram, ME | 6 |
| Kasper, ZA | 1 |
| Gilley, DR | 1 |
| Clark, AD | 1 |
| Wieser, ME | 1 |
| Bollig, CA | 1 |
| Dooley, LM | 1 |
| Biedermann, GB | 1 |
| Bongiovanni, T | 1 |
| Gan, S | 1 |
| Finlayson, E | 1 |
| Ross, J | 1 |
| Harrison, JD | 1 |
| Boscardin, J | 1 |
| Steinman, MA | 1 |
| Kuehn, BM | 1 |
| Seu, R | 1 |
| Pereira, X | 1 |
| Goriacko, P | 1 |
| Yaghdjian, V | 1 |
| Appiah, D | 1 |
| Moran-Atkin, E | 1 |
| Camacho, D | 1 |
| Kim, J | 1 |
| Choi, J | 1 |
| Castillo, F | 1 |
| Jones, JD | 1 |
| Luba, RR | 1 |
| Mogali, S | 1 |
| Foltin, RW | 1 |
| Evans, SM | 1 |
| Comer, SD | 1 |
| Jalilian Khave, L | 3 |
| Noori, M | 3 |
| Rahimi-Movaghar, A | 4 |
| Noroozi, A | 3 |
| Qureshi, R | 3 |
| Zhang, DA | 1 |
| Brenn, B | 1 |
| Cho, R | 1 |
| Samdani, A | 1 |
| Poon, SC | 1 |
| Xu, KY | 1 |
| Tardelli, VS | 1 |
| Fidalgo, TM | 1 |
| Grucza, RA | 1 |
| Gedda, C | 1 |
| Nygren, J | 1 |
| Garpenbeck, A | 1 |
| Hoffström, L | 1 |
| Thorell, A | 1 |
| Soop, M | 1 |
| de Dios, C | 1 |
| Suchting, R | 1 |
| Green, C | 1 |
| Klugh, JM | 1 |
| Harvin, JA | 1 |
| Webber, HE | 1 |
| Schmitz, JM | 1 |
| Lane, SD | 1 |
| Yoon, JH | 1 |
| Heads, A | 1 |
| Motley, K | 1 |
| Stotts, A | 1 |
| Tong, K | 1 |
| Nolan, W | 1 |
| O'Sullivan, DM | 1 |
| Sheiner, P | 1 |
| Kutzler, HL | 1 |
| Murnion, BP | 1 |
| Rivas, C | 1 |
| Demirkol, A | 1 |
| Hayes, V | 1 |
| Lintzeris, N | 1 |
| Nielsen, S | 1 |
| Kurtz, SP | 1 |
| Cicero, TJ | 1 |
| Havens, JR | 2 |
| Wiercigroch, D | 1 |
| Sheikh, H | 1 |
| Hulme, J | 1 |
| Stein, MD | 1 |
| Kenney, SR | 1 |
| Anderson, BJ | 1 |
| Conti, MT | 1 |
| Bailey, GL | 1 |
| Patrick, SW | 1 |
| Slaughter, JC | 1 |
| Harrell, FE | 1 |
| Martin, PR | 1 |
| Hartmann, K | 1 |
| Dudley, J | 1 |
| Stratton, S | 1 |
| Cooper, WO | 1 |
| Bykov, K | 1 |
| Bateman, BT | 1 |
| Franklin, JM | 1 |
| Vine, SM | 1 |
| Patorno, E | 1 |
| Ibiloye, EA | 1 |
| Barner, JC | 1 |
| Lawson, KA | 1 |
| Rascati, KL | 1 |
| Evoy, KE | 2 |
| Peckham, AM | 2 |
| Zhang, Y | 1 |
| Castracane, AR | 1 |
| Winstanley, EL | 1 |
| Oldfield, BJ | 1 |
| Vickers-Smith, R | 1 |
| Becker, WC | 1 |
| Barry, DT | 1 |
| Crystal, S | 1 |
| Gordon, KS | 1 |
| Kerns, RD | 1 |
| Rentsch, CT | 1 |
| Marshall, BDL | 1 |
| Edelman, EJ | 1 |
| Rudolf, G | 1 |
| Walsh, J | 1 |
| Plawman, A | 1 |
| Gianutsos, P | 1 |
| Alto, W | 1 |
| Mancl, L | 1 |
| Rudolf, V | 1 |
| Oltman, J | 1 |
| Militsakh, O | 1 |
| D'Agostino, M | 1 |
| Kauffman, B | 1 |
| Lindau, R | 1 |
| Coughlin, A | 1 |
| Lydiatt, W | 1 |
| Lydiatt, D | 1 |
| Smith, R | 1 |
| Panwar, A | 1 |
| Covvey, JR | 1 |
| Ochs, L | 1 |
| Fairman, KA | 1 |
| Sclar, DA | 1 |
| Throckmorton, DC | 1 |
| Gottlieb, S | 1 |
| Woodcock, J | 1 |
| Gholami, J | 1 |
| Amato, L | 1 |
| Hoseinie, L | 1 |
| Yousefi-Nooraie, R | 1 |
| Amin-Esmaeili, M | 1 |
| Wachman, EM | 1 |
| Warden, AH | 1 |
| Thomas, Z | 1 |
| Thomas-Lewis, JA | 1 |
| Shrestha, H | 1 |
| Nikita, FNU | 1 |
| Shaw, D | 1 |
| Saia, K | 1 |
| Schiff, DM | 1 |
| Gross, JL | 1 |
| Perate, AR | 1 |
| Elkassabany, NM | 1 |
| Kim, S | 1 |
| Sanders, NC | 1 |
| Mancino, MJ | 1 |
| Gentry, WB | 1 |
| Guise, JB | 1 |
| Bickel, WK | 1 |
| Thostenson, J | 1 |
| Oliveto, AH | 1 |
| Moghadam, MS | 1 |
| Alavinia, M | 1 |
| Baird, CR | 1 |
| Fox, P | 1 |
| Colvin, LA | 1 |
| Satish, R | 1 |
| Kandasamy, A | 1 |
| Jayarajan, D | 1 |
| Benegal, V | 1 |
| Smith, RV | 1 |
| Lofwall, MR | 1 |
| Bastiaens, L | 1 |
| Galus, J | 1 |
| Mazur, C | 1 |
| Weinstein, ZM | 1 |
| Cheng, DM | 1 |
| Quinn, E | 1 |
| Hui, D | 1 |
| Kim, H | 1 |
| Gryczynski, G | 1 |
| Samet, JH | 1 |
| Kheirabadi, GR | 2 |
| Ranjkesh, M | 2 |
| Maracy, MR | 2 |
| Salehi, M | 2 |
| Compton, P | 1 |
| Kehoe, P | 1 |
| Sinha, K | 1 |
| Torrington, MA | 1 |
| Ling, W | 1 |
| Nicolodi, M | 1 |
| Del Bianco, PL | 1 |
| Sicuteri, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pragmatic, Multi-centre, Open-label, Randomized, 12-month, Parallel Group, Superiority Study to Compare the Effectiveness of Subcutaneous Buprenorphine Depot (Sublocade®) vs Daily Sublingual Buprenorphine With Naloxone (Suboxone®) for the Treatment of O[NCT05594121] | Phase 4 | 90 participants (Anticipated) | Interventional | 2022-12-31 | Not yet recruiting | ||
| Linking Opioid Dependent Patients From Inpatient Detoxification to Primary Care[NCT01751789] | 335 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Optimization of Opioid Discharge Prescriptions Following Thyroid and Parathyroid Surgeries[NCT04955444] | 240 participants (Actual) | Interventional | 2021-06-14 | Completed | |||
| Post-operative Pain Control With Acetaminophen and Ibuprofen After Functional Endoscopic Sinus Surgery for Chronic Rhinosinusitis: a Prospective Study.[NCT05287217] | 60 participants (Anticipated) | Interventional | 2022-07-29 | Not yet recruiting | |||
| Use of Single Dose Pre-Operative Pregabalin for Post-Operative Analgesia in Bilateral Head and Neck Cancer Surgery: A Randomized, Double-Blinded, Placebo-Controlled Trial[NCT03714867] | Phase 4 | 0 participants (Actual) | Interventional | 2019-03-22 | Withdrawn (stopped due to Inability to recruit patients) | ||
| Opioid-Induced Hyperalgesia in Prescription Opioid Abusers: Effects of Pregabalin[NCT01821430] | Phase 2 | 4 participants (Actual) | Interventional | 2013-03-31 | Terminated (stopped due to poor recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Proportion of patients who receive new opioid discharge prescriptions at discharge following a thyroidectomy or parathyroidectomy procedure. This outcome excludes continuation of previous, chronic opioid therapy. (NCT04955444)
Timeframe: Up to 2 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Historical Control Group | 128 |
| Post-implementation Group | 28 |
Proportion of thyroidectomy and parathyroidectomy postoperative patients who receive new opioid prescriptions from the surgeon's office within 7 days of surgery including discharge prescriptions. This outcome excludes continuation of previous, chronic opioid therapy. (NCT04955444)
Timeframe: Up to 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Historical Control Group | 0 |
| Post-implementation Group | 0 |
Proportion of thyroidectomy and parathyroidectomy postoperative patients with opioid discharge prescriptions exceeding the recommended dose of 112.5 oral MMEs (NCT04955444)
Timeframe: Up to 2 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Historical Control Group | 52 |
| Post-implementation Group | 8 |
Proportion of thyroidectomy and parathyroidectomy postoperative patients with opioid discharge prescriptions exceeding 5 days of therapy (NCT04955444)
Timeframe: Up to 2 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Historical Control Group | 27 |
| Post-implementation Group | 5 |
Proportion of thyroidectomy and parathyroidectomy postoperative patients with opioid prescriptions exceeding 50 oral MMEs/day when new, postoperative discharge prescriptions are added to existing opioid therapy (NCT04955444)
Timeframe: Up to 2 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Historical Control Group | 9 |
| Post-implementation Group | 0 |
3 reviews available for gabapentin and Addiction, Opioid
| Article | Year |
|---|---|
Pharmacological therapies for management of opium withdrawal.
Topics: Amantadine; Amines; Baclofen; Buprenorphine; Clonidine; Cyclohexanecarboxylic Acids; Gabapentin; gam | 2018 |
Pain Management in Trauma in the Age of the Opioid Crisis.
Topics: Acetaminophen; Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Child; Gabapentin; Humans | 2019 |
The unsuspected threat of three opioid-like substitutes.
Topics: Analgesics; Antidiarrheals; Gabapentin; Humans; Loperamide; Mitragyna; Opiate Substitution Treatment | 2019 |
8 trials available for gabapentin and Addiction, Opioid
| Article | Year |
|---|---|
Gabapentin and intrathecal morphine combination therapy results in decreased oral narcotic use and more consistent pain scores after posterior spinal fusion for adolescent idiopathic scoliosis.
Topics: Adolescent; Analgesia, Patient-Controlled; Analgesics, Opioid; Gabapentin; Humans; Kyphosis; Morphin | 2021 |
Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder.
Topics: Alcoholism; Analgesics, Opioid; Cross-Over Studies; Double-Blind Method; Ethanol; Gabapentin; Humans | 2022 |
Acute Experimental Pain Responses in Methadone- and Buprenorphine/Naloxone-Maintained Patients Administered Additional Opioid or Gabapentin: A Double-Blind Crossover Pilot Study.
Topics: Analgesics, Opioid; Australia; Buprenorphine; Cross-Over Studies; Double-Blind Method; Gabapentin; H | 2020 |
Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure.
Topics: Adult; Amines; Buprenorphine; Cyclohexanecarboxylic Acids; Diagnostic and Statistical Manual of Ment | 2013 |
The effects of gabapentin on methadone based addiction treatment: a randomized controlled trial.
Topics: Adult; Amines; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug Therapy, C | 2013 |
Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Blind Method; Female; Gabapentin; gam | 2008 |
Gabapentin improves cold-pressor pain responses in methadone-maintained patients.
Topics: Adult; Amines; Analgesics, Non-Narcotic; Cold Temperature; Cyclohexanecarboxylic Acids; Double-Blind | 2010 |
Importance of gabapentin dose in treatment of opioid withdrawal.
Topics: Adult; Amines; Analgesics, Opioid; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relat | 2011 |
31 other studies available for gabapentin and Addiction, Opioid
| Article | Year |
|---|---|
Nonmedical use of gabapentin and opioid agonist medications in treatment-seeking individuals with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Gabapentin; Humans; Methadone; Opiate Su | 2022 |
Effectiveness of gabapentin in reducing opioid requirements after radiation in head and neck cancer in a single institution.
Topics: Analgesics, Opioid; Gabapentin; Head and Neck Neoplasms; Humans; Opioid-Related Disorders; Retrospec | 2022 |
Prolonged use of newly prescribed gabapentin after surgery.
Topics: Aged; Analgesics, Opioid; Female; Gabapentin; Humans; Male; Medicare; Opioid-Related Disorders; Pain | 2022 |
Growing Role of Gabapentin in Opioid-Related Overdoses Highlights Misuse Potential and Off-label Prescribing Practices.
Topics: Analgesics, Opioid; Central Nervous System Agents; Drug Overdose; Gabapentin; Humans; Off-Label Use; | 2022 |
Effectiveness of Bariatric Surgery Targeting Opioid Prescriptions (BSTOP) protocol on postoperative pain control.
Topics: Analgesics, Opioid; Bariatric Surgery; Gabapentin; Humans; Morphine; Opioid-Related Disorders; Pain, | 2023 |
Management of gabapentin misuse in a patient with previous history of opioid use disorder: Case report.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Gabapentin; Humans; Male; Opioid-Related Disorders | 2023 |
Management of gabapentin misuse in a patient with previous history of opioid use disorder: Case report.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Gabapentin; Humans; Male; Opioid-Related Disorders | 2023 |
Management of gabapentin misuse in a patient with previous history of opioid use disorder: Case report.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Gabapentin; Humans; Male; Opioid-Related Disorders | 2023 |
Management of gabapentin misuse in a patient with previous history of opioid use disorder: Case report.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Gabapentin; Humans; Male; Opioid-Related Disorders | 2023 |
Management of gabapentin misuse in a patient with previous history of opioid use disorder: Case report.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Gabapentin; Humans; Male; Opioid-Related Disorders | 2023 |
Management of gabapentin misuse in a patient with previous history of opioid use disorder: Case report.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Gabapentin; Humans; Male; Opioid-Related Disorders | 2023 |
Management of gabapentin misuse in a patient with previous history of opioid use disorder: Case report.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Gabapentin; Humans; Male; Opioid-Related Disorders | 2023 |
Management of gabapentin misuse in a patient with previous history of opioid use disorder: Case report.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Gabapentin; Humans; Male; Opioid-Related Disorders | 2023 |
Management of gabapentin misuse in a patient with previous history of opioid use disorder: Case report.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Gabapentin; Humans; Male; Opioid-Related Disorders | 2023 |
Understanding motivations and use typologies of gabapentin with opioid agonist medications.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Gabapentin; Humans; Methadone; Motivatio | 2023 |
Understanding motivations and use typologies of gabapentin with opioid agonist medications.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Gabapentin; Humans; Methadone; Motivatio | 2023 |
Understanding motivations and use typologies of gabapentin with opioid agonist medications.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Gabapentin; Humans; Methadone; Motivatio | 2023 |
Understanding motivations and use typologies of gabapentin with opioid agonist medications.
Topics: Analgesics, Opioid; Buprenorphine; Cross-Sectional Studies; Gabapentin; Humans; Methadone; Motivatio | 2023 |
Effect of gabapentin on length of stay, opioid use, and pain scores in posterior spinal fusion for adolescent idiopathic scoliosis: a retrospective review across a multi-hospital system.
Topics: Adolescent; Analgesics, Opioid; Child; Gabapentin; Humans; Length of Stay; Multi-Institutional Syste | 2023 |
Gabapentin Use Among Individuals Initiating Buprenorphine Treatment for Opioid Use Disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Case-Control Studies; Drug-Related Side Effects and Advers | 2023 |
Multimodal Analgesia Bundle and Postoperative Opioid Use Among Patients Undergoing Colorectal Surgery.
Topics: Agnosia; Analgesia; Analgesics, Opioid; Clonidine; Cohort Studies; Colorectal Surgery; Female; Gabap | 2023 |
An opioid-minimizing multimodal pain regimen reduces opioid exposure and pain in trauma-injured patients at high risk for opioid misuse: Secondary analysis from the mast trial.
Topics: Acetaminophen; Analgesics; Analgesics, Opioid; Bayes Theorem; Gabapentin; Humans; Morphine Derivativ | 2023 |
Implementation of a Multimodal Pain Management Order Set Reduces Perioperative Opioid Use after Liver Transplantation.
Topics: Acetaminophen; Adult; Analgesics; Analgesics, Opioid; Drug Therapy, Combination; Female; Gabapentin; | 2019 |
An ethnographic decision model of the initiation of gabapentin misuse among prescription and/or illicit opioid (mis)user.
Topics: Adult; Anthropology, Cultural; Decision Theory; Drug Users; Female; Gabapentin; Humans; Male; Opioid | 2019 |
A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use.
Topics: Acamprosate; Addiction Medicine; Adult; Aged; Alcohol Deterrents; Alcoholism; Buprenorphine; Emergen | 2020 |
Prescribed and non-prescribed gabapentin use among persons seeking inpatient opioid detoxification.
Topics: Analgesics, Opioid; Drug Overdose; Female; Gabapentin; Humans; Inpatients; Male; Opioid-Related Diso | 2020 |
Development and Validation of a Model to Predict Neonatal Abstinence Syndrome.
Topics: Adult; Analgesics; Antiemetics; Antipsychotic Agents; Benzodiazepines; Bupropion; Female; Gabapentin | 2021 |
Association of Gabapentinoids With the Risk of Opioid-Related Adverse Events in Surgical Patients in the United States.
Topics: Aged; Analgesics, Opioid; Drug Overdose; Drug Therapy, Combination; Female; Gabapentin; Humans; Male | 2020 |
Prevalence of and Factors Associated with Gabapentinoid Use and Misuse Among Texas Medicaid Recipients.
Topics: Adolescent; Adult; Analgesics, Opioid; Female; Gabapentin; Humans; Male; Medicaid; Middle Aged; Neur | 2021 |
Assessment of gabapentin misuse using prescription drug monitoring program data.
Topics: Adult; Analgesics, Opioid; Gabapentin; Humans; Opioid-Related Disorders; Prescription Drug Misuse; P | 2021 |
Sociodemographic and clinical correlates of gabapentin receipt with and without opioids among a national cohort of patients with HIV.
Topics: Analgesics, Opioid; Chronic Pain; Cohort Studies; Gabapentin; HIV Infections; Humans; Opioid-Related | 2022 |
A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment.
Topics: Adult; Amines; Analgesics, Opioid; Buprenorphine; Clonidine; Counseling; Cyclohexanecarboxylic Acids | 2018 |
Multimodal Analgesia in Outpatient Head and Neck Surgery: A Feasibility and Safety Study.
Topics: Acetaminophen; Ambulatory Surgical Procedures; Analgesia; Analgesics; Analgesics, Non-Narcotic; Anti | 2017 |
Multimodal Analgesia in Outpatient Head and Neck Surgery: A Feasibility and Safety Study.
Topics: Acetaminophen; Ambulatory Surgical Procedures; Analgesia; Analgesics; Analgesics, Non-Narcotic; Anti | 2017 |
Multimodal Analgesia in Outpatient Head and Neck Surgery: A Feasibility and Safety Study.
Topics: Acetaminophen; Ambulatory Surgical Procedures; Analgesia; Analgesics; Analgesics, Non-Narcotic; Anti | 2017 |
Multimodal Analgesia in Outpatient Head and Neck Surgery: A Feasibility and Safety Study.
Topics: Acetaminophen; Ambulatory Surgical Procedures; Analgesia; Analgesics; Analgesics, Non-Narcotic; Anti | 2017 |
Multimodal Analgesia in Outpatient Head and Neck Surgery: A Feasibility and Safety Study.
Topics: Acetaminophen; Ambulatory Surgical Procedures; Analgesia; Analgesics; Analgesics, Non-Narcotic; Anti | 2017 |
Multimodal Analgesia in Outpatient Head and Neck Surgery: A Feasibility and Safety Study.
Topics: Acetaminophen; Ambulatory Surgical Procedures; Analgesia; Analgesics; Analgesics, Non-Narcotic; Anti | 2017 |
Multimodal Analgesia in Outpatient Head and Neck Surgery: A Feasibility and Safety Study.
Topics: Acetaminophen; Ambulatory Surgical Procedures; Analgesia; Analgesics; Analgesics, Non-Narcotic; Anti | 2017 |
Multimodal Analgesia in Outpatient Head and Neck Surgery: A Feasibility and Safety Study.
Topics: Acetaminophen; Ambulatory Surgical Procedures; Analgesia; Analgesics; Analgesics, Non-Narcotic; Anti | 2017 |
Multimodal Analgesia in Outpatient Head and Neck Surgery: A Feasibility and Safety Study.
Topics: Acetaminophen; Ambulatory Surgical Procedures; Analgesia; Analgesics; Analgesics, Non-Narcotic; Anti | 2017 |
Predictors of Gabapentin Overuse With or Without Concomitant Opioids in a Commercially Insured U.S. Population.
Topics: Age Factors; Analgesics, Opioid; Drug Utilization; Gabapentin; Humans; Hypnotics and Sedatives; Odds | 2018 |
The FDA and the Next Wave of Drug Abuse - Proactive Pharmacovigilance.
Topics: Amines; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Drug Utilization | 2018 |
Impact of psychiatric medication co-exposure on Neonatal Abstinence Syndrome severity.
Topics: Adult; Analgesics, Opioid; Benzodiazepines; Buprenorphine; Female; Gabapentin; Humans; Infant; Infan | 2018 |
Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers.
Topics: Amines; Behavior, Addictive; Cyclohexanecarboxylic Acids; Data Collection; Drug Synergism; Gabapenti | 2014 |
Gabapentin dependence in a patient with opioid dependence syndrome.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; | 2015 |
Abuse and diversion of gabapentin among nonmedical prescription opioid users in Appalachian Kentucky.
Topics: Adult; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; | 2015 |
Abuse of Gabapentin is Associated with Opioid Addiction.
Topics: Adult; Amines; Attention Deficit Disorder with Hyperactivity; Comorbidity; Criminals; Cyclohexanecar | 2016 |
Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine.
Topics: Adult; Amines; Analgesics, Opioid; Buprenorphine; Clonidine; Cyclohexanecarboxylic Acids; Female; Ga | 2017 |
Modulation of excitatory amino acids pathway: a possible therapeutic approach to chronic daily headache associated with analgesic drugs abuse.
Topics: Acetates; Adult; Amines; Chronic Disease; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagon | 1997 |